Review




Structured Review

BioNTech cancer mrna vaccine fixvac (bnt 111)
Cancer Mrna Vaccine Fixvac (Bnt 111), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cancer mrna vaccine fixvac (bnt 111)/product/BioNTech
Average 90 stars, based on 1 article reviews
cancer mrna vaccine fixvac (bnt 111) - by Bioz Stars, 2026-06
90/100 stars

Images



Similar Products

90
BioNTech cancer mrna vaccine fixvac (bnt 111)
Cancer Mrna Vaccine Fixvac (Bnt 111), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cancer mrna vaccine fixvac (bnt 111)/product/BioNTech
Average 90 stars, based on 1 article reviews
cancer mrna vaccine fixvac (bnt 111) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
BioNTech bnt-111
Bnt 111, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt-111/product/BioNTech
Average 90 stars, based on 1 article reviews
bnt-111 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
BioNTech fixvac (bnt 111)
Clinical trials with TAA and neoantigens-based cancer vaccines encoding
Fixvac (Bnt 111), supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fixvac (bnt 111)/product/BioNTech
Average 90 stars, based on 1 article reviews
fixvac (bnt 111) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Clinical trials with TAA and neoantigens-based cancer vaccines encoding

Journal: Exploration of Targeted Anti-tumor Therapy

Article Title: Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises

doi: 10.37349/etat.2022.00111

Figure Lengend Snippet: Clinical trials with TAA and neoantigens-based cancer vaccines encoding

Article Snippet: Skin , Melanoma Stage IIIB, C, and IV , Phase I (Lipo-MERIT trial) , FixVac (BNT 111) , 4 TAA (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE) , Liposomal RNA (RNA-LPX) vaccine , Strong CD4 + and CD8 + T-cell immunity against the vaccine antigens/antigen-specific cytotoxic T-cell responses in some responders reach magnitudes and are durable , BioNTech SE (Germany) , NCT02410733 , [ ] .

Techniques: Clinical Proteomics, Immunopeptidomics, Vaccines, Formulation, Recombinant, Modification, Virus, Adjuvant, Mutagenesis, Ex Vivo